Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab.
Brodalumab
Pharmacology
Psoriasis
Quality of life
Ustekinumab
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
29
01
2021
accepted:
29
04
2021
pubmed:
15
5
2021
medline:
15
5
2021
entrez:
14
5
2021
Statut:
ppublish
Résumé
Targeted biological therapies for psoriasis have resulted in significant benefits, with therapeutic goals such as clear or almost clear skin accompanied by improvements in health-related quality of life (HRQoL). The objective of this study was to compare the effects of 52 weeks of treatment with brodalumab or ustekinumab on HRQoL in patients with moderate-to-severe plaque psoriasis. Data were pooled from two randomised controlled phase 3 trials (AMAGINE-2 and -3) which included patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab 45 or 90 mg for 52 weeks. HRQoL outcomes were measured using the Dermatology Life Quality Index (DLQI) as well as the DLQI-Relevant (DLQI-R) version which excludes 'not relevant' responses. A total of 929 patients were included, 339 in the brodalumab group and 590 in the ustekinumab group. A significantly greater reduction (improvement) in DLQI score from baseline was observed in the brodalumab group compared with the ustekinumab group at weeks 4 [least-squares (LS) mean difference - 2.9, 95% confidence interval [CI] - 3.6 to - 2.2; p < 0.001), 12 (LS mean difference - 0.85, 95% CI - 1.5 to - 0.2; p = 0.01) and 52 (LS mean difference - 0.94, 95% CI - 1.6 to - 0.2; p = 0.009)]. Significantly greater proportions of patients treated with brodalumab achieved a DLQI score of 0 at weeks 4 (15.0 vs. 5.4%; p < 0.0001), 12 (37.5 vs. 28.0%; p = 0.0140) and 52 (46.3 vs. 30.3%; p < 0.0001), or of ≤ 1 [DLQI (0/1): 33.9 vs. 15.4%, 59.9 vs. 45.6% and 54.9 vs. 39.8%, respectively; all p < 0.0001]. Similar results were observed using the DLQI-R scoring system. Significantly more patients achieved a ≥ 4 or ≥ 5 improvement in DLQI with brodalumab compared to ustekinumab at weeks 4 and 52. Treatment with brodalumab was associated with significantly more patients achieving a DLQI of 0 compared to ustekinumab for all domains after 4 and 52 weeks. Brodalumab was associated with a significantly greater improvement in HRQoL compared to ustekinumab in patients with moderate-to-severe psoriasis.
Identifiants
pubmed: 33988818
doi: 10.1007/s13555-021-00545-5
pii: 10.1007/s13555-021-00545-5
pmc: PMC8322208
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1265-1275Informations de copyright
© 2021. The Author(s).
Références
Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–20.
doi: 10.1111/jdv.14007
Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162(1):137–46.
doi: 10.1111/j.1365-2133.2009.09491.x
Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457–65.
doi: 10.1016/j.jaad.2009.09.014
Gordon KB, Kimball AB, Chau D, et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure the Psoriasis Symptom Inventory. Br J Dermatol. 2014;170(3):705–15.
doi: 10.1111/bjd.12636
Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179:320–8.
pubmed: 29488226
Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-69.e9.
doi: 10.1016/j.jaad.2016.08.008
Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–23.
doi: 10.1111/bjd.15666
Puig L, Augustin M, Blauvelt A, et al. Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study. J Am Acad Dermatol. 2018;78(4):741–8.
doi: 10.1016/j.jaad.2017.10.025
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–28.
doi: 10.1056/NEJMoa1503824
Rencz F, Poór AK, Péntek M, et al. A detailed analysis of “not relevant” responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol. 2018;32(5):783–90.
doi: 10.1111/jdv.14676
Rencz F, Gulácsi L, Péntek M, et al. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. Br J Dermatol. 2018;179(5):1102–8.
doi: 10.1111/bjd.16927
Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–92.
doi: 10.2165/00128071-200506060-00005
Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):559–68.
doi: 10.1586/14737167.2014.914437
Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb). 2019;9:5–18.
doi: 10.1007/s13555-018-0279-5
Lebwohl MG, Blauvelt A, Menter A, et al. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, open-label, phase II study. Am J Clin Dermatol. 2019;20(6):863–71.
doi: 10.1007/s40257-019-00466-2
Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–72.
doi: 10.1111/j.1365-2133.2012.10901.x
Augustin M, Blome C, Paul C, et al. Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):294–303.
doi: 10.1111/jdv.13823
Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27–33.
doi: 10.1159/000365390
Warren RB, Hansen JB, Reich K, et al. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16816.10.1111/jdv.16816 .
doi: 10.1111/jdv.16816.10.1111/jdv.16816
pubmed: 32979235
pmcid: 7496750
Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235–9.
doi: 10.3109/09546634.2014.943687
Revicki DA, Jin Y, Wilson HD, et al. Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2014;25(1):8–14.
doi: 10.3109/09546634.2013.769042
Abrouk M, Nakamura M, Zhu TH, et al. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017;28(6):488–91.
doi: 10.1080/09546634.2016.1278198
Hesselvig JH, Egeberg A, Loft ND, et al. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol. 2018;98(3):335–9.
doi: 10.2340/00015555-2833
Loft ND, Egeberg A, Rasmussen MK, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a Danish nationwide study. Acta Derm Venereol. 2019;99(13):1224–30.
doi: 10.2340/00015555-3331